Floatz logo

CYTARABINE

Acute Myeloblastic Leukemia Without Maturation

Northwestern UniversitySmall moleculePhase 3Active
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Acute Myeloblastic Leukemia Without Maturation cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB
Idarubicin
Bruno C. Medeiros
Phase 3BBB
Mitoxantrone
Stanford University
Phase 2BBB

View all 50 →

Same molecule, other indications

CYTARABINE is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →